See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Vatican
Wrestling
Baseball
Donald Trump
MLS
Tennis
Hockey
Israel-Hamas Conflict
Elon Musk
Hamas
Published • loading... • Updated

Rare Liver Cancer Decoded: Groundbreaking Clinical Trial Begins

Summary by Sci Tech Daily
FLC is a rare liver cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial offer hope for effective treatments. Fibrolamellar hepatocellular carcinoma (FLC), like many rare diseases, strikes a small but vulnerable group—primarily children, adolescents, and young adults—with devastating impact. Its symptoms vary widely between individuals, often leading to [...]

3 Articles

All
Left
Center
1
Right
Sci Tech DailySci Tech Daily

Rare Liver Cancer Decoded: Groundbreaking Clinical Trial Begins

FLC is a rare liver cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial offer hope for effective treatments. Fibrolamellar hepatocellular carcinoma (FLC), like many rare diseases, strikes a small but vulnerable group—primarily children, adolescents, and young adults—with devastating impact. Its symptoms vary widely between individuals, often leading to [...]

Read Full Article
Scientific InquirerScientific Inquirer

Research using non-toxic bacteria to fight high-mortality cancers prepares for clinical trials - Scientific Inquirer

A University of Massachusetts Amherst-Ernest Pharmaceuticals team of scientists has made “exciting,” patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds promise for very safe and more effective treatment of cancers with high mortality rates, including liver, ovarian and metastatic breast cancer. Clinical trials with participating cance…

Read Full Article
UMass AmherstUMass Amherst

Research Using Non-Toxic Bacteria to Fight High-Mortality Cancers Prepares for Clinical Trials

The latest breakthrough from a team of UMass Amherst and Ernest Pharmaceutical researchers uses aspirin in its targeted drug delivery therapy.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

UMass Amherst broke the news in on Sunday, January 19, 2025.
Sources are mostly out of (0)

Similar News Topics

Research

Research

Science

Science

Amherst, Massachusetts

Amherst, Massachusetts

News
For You
Search
BlindspotLocal